Full Name
Zdraveska, Marija
Vernacular Name
Zdraveska M.
 
Variants
Zdraveska M
M. Zdraveska
Marija Zdraveska
Lazarevska Marija
Lazarevska M
Здравеска Марија
Здравеска М
Лазаревска Марија
Лазаревска М
Marija Zdravevska
 
Main Affiliation
 
Loading... 2 0 5 0 false
Loading... 3 0 5 0 false

Refined By:
Date Issued:  [2010 TO 2019]
Author:  Monreal M
Fulltext:  No Fulltext

Results 1-5 of 5 (Search time: 0.01 seconds).

PreviewTitleAuthor(s)Issue DateType
1Clinical Characteristics and Outcomes of Patients with Lung Cancer and Venous ThromboembolismRuiz-Artacho P,; Trujillo-Santos J,; López-Jiménez L,; Font C,; Díaz-Pedroche MDC,; Sánchez Muñoz-Torrero JF,; Peris ML,; Skride A,; Maestre A,; Monreal M; RIETE Investigators; Bosevski M ; Zdraveska M 2018Article
2Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism.Peris M; Jiménez D; Maestre A; Font C; Tafur AJ; Mazzolai L; Xifre B; Skride A; Dentali F; Monreal M; RIETE Investigators; Bosevski M ; Zdraveska M 2016Article
3Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis.Tafur AJ,; Caprini JA,; Cote L; Trujillo-Santos J; Del Toro J,; Garcia-Bragado F; Tolosa C,; Barillari G,; Visona A,; Monreal M; RIETE Investigators; Bosevski, M ; Zdraveska M 2017Article
4Venous thromboembolism in centenarians: Findings from the RIETE registryLacruz B; Tiberio G; Núñez MJ; López-Jiménez L; Riera-Mestre A; Tiraferri E; Verhamme P; Mazzolai L; González J; Monreal M; RIETE Investigators; Bosevski M ; Zdraveska M 2016Article
5Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous ThromboembolismChai-Adisaksopha C; Iorio A; Crowther MA; de Miguel J; Salgado E; Marija Zdraveska ; Fernández-Capitán C; Nieto JA; Barillari G; Bertoletti L; Monreal M; RIETE investigatorsApr-2018Article